FCM
VRNA

Findell Capital Management’s Verona Pharma VRNA Stock Holding History

Findell Capital Management’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-180,000
Closed -$8.36M – 18
2024
Q4 		$8.36M Buy
+180,000
New +$6.76M 3.42% 10

Other funds holding VRNA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Findell Capital Management's VRNA Position: Q1 2025 in Review

Findell Capital Management sold out of Verona Pharma (VRNA) in Q1 2025, closing a stake of 180,000 shares — an estimated $8.36M sold.

Findell Capital Management first reported a position in VRNA in Q4 2024 and held it in 1 quarter. The position peaked at $8.36M in Q4 2024. 258 funds tracked by Wall St. Rank hold VRNA as of Q1 2025.

  • Findell Capital Management reported no remaining Verona Pharma position as of Q1 2025 after selling out during the quarter.
  • Findell Capital Management sold 180,000 Verona Pharma shares in Q1 2025, an estimated $8.36M.
  • Findell Capital Management first reported a position in Verona Pharma in Q4 2024 and held it in 1 quarter.
  • Findell Capital Management's Verona Pharma position peaked at $8.36M in Q4 2024.
  • 258 funds tracked by Wall St. Rank held Verona Pharma as of Q1 2025.

Based on Findell Capital Management's 13F filing for Q1 2025, filed 15 May 2025.